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Introduction
The differentiation of CD4 T helper (Th) cells 
plays a critical role in the immune response. 
Four major Th cell subsets have been described: 
Th1 produce IFN-γ; Th2 are characterised by 
the secretion of interleukin (IL)-4, IL-5 and 
IL-13; Th17 produce IL-17; and Treg cell sub-
sets secrete transforming growth factor-β 
(TGF-β).
Th1 and Th2 have been the sole paradigm of T 
helper functional diversification for many years.1 
Both cell types arise after the sustained activation 
of uncommitted Th0 cell precursors and 
are characterised by the expression of mutually 
exclusive sets of cytokines. This cellular dichotomy 
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has been mechanistically explained by the mutual 
inhibition of the master transcription factors T-bet 
and GATA-3 at individual cell level, and by cross-
regulatory mechanisms at cell population level.2 
However, the identification of Th17 and TGF-
secreting Treg cells has complicated the picture of 
the CD4+ effector T cell programme. Neither have 
yet been rigorously analysed, but recent acquisi-
tions suggest that memory cells need to be flexible 
in order to be able to protect against a re-encoun-
tered pathogen.3 Th17 cells express the transcrip-
tion factor retinoic acid-related orphan receptor γt 
(RORγt) and IL-17A, which not only protect against 
fungi and various other extracellular bacteria, but 
also play a pathogenetic role in the development of 
autoimmune inflammatory disease.
Treg-controlled self-reactive T cells escape neg-
ative selection, and control excessive effector T cell 
responses against exogenous antigens when these 
become dangerous for the body. They suppress both 
Th1 and Th2 responses by means of contact-
dependent mechanisms and/or the production of 
IL-10 and TGF-β.4 It has been shown that the IL-l0 
secreted by these cells effectively prevents chronic 
intestinal inflammation, and it has been postulated 
that TGF-β is involved in maintaining tolerance to 
dietary antigens.5 TGF-β1 can promote the devel-
opment of Th17 effector and adaptive Treg cells, 
whereas the simultaneous production of IL-6 con-
tributes to development of Th17 cells but inhibits 
Treg cells.4,6 The central transcription factors for 
Th17 (RORγt) and Treg (Foxp3) both depend on 
TGF-β signalling, and their direct interactions 
establish a competitive antagonism that determines 
the specification of a Th17 or induced Treg line-
age.7 Tyrosine phosphatase SHP-1 is a critical regu-
lator of Th17: its impairment promotes Th17 
development, and the ex vivo disruption of its activ-
ity in T cells leads to a hyper-response to stimula-
tion by IL6 and IL21. It has also been found that 
tyrosine phosphatase SHP-1 decreases the overall 
cytokine-induced phosphorylation of STAT3 in pri-
mary CD4+ T cells.8
One important characteristic of Th17 and Treg 
cells is their ability to produce IL-9. The IL-9 pro-
duced by Th17 is pro-inflammatory in a standard 
myelin oligodendrocyte glycoprotein peptide-
induced model of experimental autoimmune 
encephalomyelitis,9 whereas the IL-9 produced by 
Treg cells mediates graft tolerance by means of a 
mast cell-dependent process.10 IL-9 may therefore 
be inflammatory or regulatory depending on the 
context.
Nevertheless, current evidence indicates that 
late Th cell differentiation pathways are more com-
plex and probably include other, non-canonical 
cell types. Early phenomenological models repre-
sented the development of Th1 vs. Th2 responses 
from naïve Th0 cells using ordinary differential 
equations. However, although the stable states cor-
responding to canonical Th1, Th2, Th17 and Treg 
subtypes are readily identified, they also co-exist 
with other hybrid cell types that co-express a com-
bination of Th1, Th2 and Treg markers in an envi-
roment-dependent manner. The in vitro stimulation 
of Th2 cells in the presence of TGF-β generates a 
non-canonical cell type expressing IL-10 and IL-9 
in the absence of Foxp3,2 and this subset of differ-
entiated T cells has led to a re-evaluation of the 
classification of IL-9 as a type 2 cytokine. In vitro 
IL-9-producing T cells seem to be a distinct subset 
of ‘Th9’ cells that depend on TGF-β signalling.11 
TGF-β can alter Th2 cells to such an extent that 
they lose their previous characteristics, including 
the expression of GATA-3 and the ‘signature’ 
cytokines IL-4, IL-5 and IL-13.3
It has also been shown that IL-25 (IL-17-E), a 
member of the IL-17 cytokine family, plays a role 
in the regulation of ‘Th9’ cells. IL-25 can be found 
in the large intestine (particularly in intestinal epi-
thelial cells) and is involved in the maintenance of 
intestinal homeostasis, but is not expressed in 
germ-free mice.12 The requirement of TGF-β and 
IL-4 for IL-25-dependent IL-9 production can be 
by-passed by the retroviral expression of IL-17RB 
in T cells or in transgenic mice in which IL-17RB 
expression is controlled by the CD4 promoter, thus 
suggesting that TGF-β and IL-4 render T cells 
IL-25-responsive by inducing IL-17RB expres-
sion.11 It has been reported that a number of innate 
immune cells responsive to IL-25 (including 
monocytes and NKT cells) express functional 
IL-17RB, and that their treatment with IL-25 
induces Th2 cytokine production. Three groups 
have recently and independently identified a new 
population of innate effector cells that are innate 
IL-25 responders, but it is still unclear whether 
these are the same population and function in other 
diseases associated to Th2-cells.13
The primary aim of this study was to evaluate 
serum IL-9 levels in inflammatory bowel disease 
(IBD) patients, and their relationships with the 
Defendenti et al. 571
clinical features of the disease. We also studied the 
levels of interferon-γ (IFN-γ), Th2 cytokines (IL-4, 
IL-5 and IL-13), and IL-6 in order to clarify the 
context in which IL-9 is produced.
Materials and methods
Patients
Blood samples were randomly obtained from 43 
IBD patients attending Fatebenefratelli Hospital in 
Milan, Italy: five untreated patients with inactive 
disease, 29 mesalazine-treated patients with mild 
and moderate  disease, and nine mesalazine-treated 
patients with severe disease. The diagnosis of IBD 
was confirmed by means of standard endoscopic 
and histological criteria (the additional haematoxy-
lin and eosin staining of each sample). Their clini-
cal and immunological data were obtained from 
their medical records; 97% of the patients did not 
have any other relevant symptoms.
The serum levels of the studied cytokines were 
also measured in 10 controls randomly selected 
from blood donors with a negative history for IBD.
The study was approved by the hospital’s Ethics 
Committee, and the patients were enrolled after 
signing an informed consent form in accordance 
with the Declaration of Helsinki.
Sample collection and management
The 10 mL venous blood samples for cytokine 
analysis were collected in pyrogen-free tubes 
between 08:00 and 10:00, and then immediately 
centrifuged at 3000 rpm for 15 min. The serum 
samples were aliquoted and stored at −80°C. The 
samples were frozen and thawed only once.
Enzyme-linked immunosorbent assays (ELISA)
Serum IL-9, IFN-γ, IL-4, IL-5, IL-13 and IL-6 lev-
els were assayed in duplicate using commercial 
ELISA kits (Human IL ELISA Ready-Set-Go, 
eBioscience, San Diego, CA, USA) in accordance 
with the instructions of the manufacturer. After 
specific anti-human IL antibody adhesion to 
microwells, the human IL present in the sample or 
standard binds to the adsorbed antibodies, and 
then the addition of a biotin-conjugated anti-
human IL antibody binds to the human IL captured 
by the first antibody. The reaction was revealed 
by means of streptavidin/horseradish peroxidase 
(HRP) staining, the coloured product of which is 
proportionate to the amount of human IL in the 
sample or standard. The reaction was terminated 
by adding H2SO4 (sulphuric) acid (3 mol/L), and 
absorbance was measured at 450 nm. A standard 
curve was prepared using seven human IL stand-
ard dilutions. The limit of detection was 6 pg/mL: 
values of 6–10 pg/mL were considered borderline, 
and those of >10 pg/mL positive.
Clinical scores
All of the patients were diagnosed as having 
Crohn’s disease (CD) or ulcerative colitis (UC) on 
the basis of standard endoscopic, histological, bar-
ium contrast enema, or other recognised 
criteria.14,15
The activity of CD was defined by means of the 
Crohn’s Disease Activity Index (CDAI) and mark-
ers of inflammation.16 The CDAI is based on eight 
factors, the scores of which are totalled after adjust-
ment with a weighting factor: the number of liquid 
or soft stools each day for 7 days; abdominal pain 
each day for 7 days (severity graded 0–3); subjec-
tively assessed general wellbeing each day for 
7 days (from 0 = well to 4 = terrible); the presence 
of complications such as arthralgia or frank arthri-
tis, inflammation of the iris or uveitis, erythema 
nodosum, pyoderma gangrenosum or aphthous 
ulcers, anal fissures, fistulae or abscesses, fever; 
the need to use loperamide or opiates for diarrhoea; 
the presence of an abdominal mass (0 = absent, 
2 = questionable, 5 = definite); haematocrit levels 
of <0.47 in men or <0.42 in women; and percent-
age deviation from standard weight. A score of 
⩽150 was defined as inactive disease (remission), 
and scores of 151–220, 221–450 and >450 points 
as mildly, moderately and highly active disease, 
respectively. Disease activity was evaluated at the 
time of serum collection.
The activity of UC was defined using the 
30-point Clinical Colitis Activity Index (CCAI):17 
a score of 0–4 was defined as inactive disease 
(remission), and scores of 5–10, 11–17 and ⩾18 as 
mildly, moderately and highly active disease, 
respectively.
Statistical analysis
The continuous variables are expressed as mean 
values and standard deviation, and were compared 
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using the unpaired Student’s t test; the categorical 
variables are expressed as absolute and relative fre-
quencies, and were compared using the chi-squared 
test. The data were analysed using the Statistical 
Package for Social Sciences (SPSS 13.0, SPSS 
Inc., Chicago, IL, USA). All of the tests were two-
sided, and P values of <0.05 were considered sta-
tistically significant.
Results
Study population
Table 1 shows the demographic and clinical char-
acteristics of the study population.
Cytokine background in IBD patients
All of the samples were negative for Th2 cytokines 
(IL-4, IL-5 and IL-13) (Table 2). Ninety-three per-
cent of the patients were positive or borderline for 
IFN-γ, and their IFN-γ levels correlated with disease 
activity (P = 0.045) (Table 3). The absolute IFN-γ 
levels in the positive patients varied widely from a 
minimum of 11 pg/mL to a maximum of 500 pg/mL 
(average 83 ± 29.8 pg/mL). Furthermore, the fact 
that diagnosis, therapy and disease duration had no 
effect on cytokine levels suggests that Th1 plays a 
role in both bowel diseases.
Twenty-three patients (53%) were positive for 
IL-6 (Table 2), the presence of which was not associ-
ated with disease activity (P = 0.5) (Table 4). The 
absolute levels of IL-6 in the positive patients were 
20 ± 3.2 pg/mL, and were lower and more constant 
than IFN-γ levels. The role of IL-6 was independent 
of Th2 cytokines and did not correlate with IFN-γ 
levels. Furthermore, the levels of IL-6 did not distin-
guish the patients with UC from those with CD, 
although 72% of the IL-9 positive patients were also 
positive for IL-6. In this Th1 habitus, the simultane-
ous production of IL-6 and IL-9 suggests the devel-
opment of Th17 cells and the inhibition of Treg cells, 
and the combination of these cytokines suggests the 
presence of a cell network that includes Th1 cells, 
monocytes and cells producing IL-9. Eighteen 
patients (41%) were positive for IL-9, which was 
associated with a severe prognosis (P <0.001). The 
levels of IL-9 were always >10 pg/mL (mean value, 
40 ± 5 pg/mL), and never borderline, whereas IFN-γ 
and IL-6 levels were borderline in 13 and six cases, 
respectively (Table 2). There was a significant asso-
ciation between IL-9 levels and disease activity in 
the patients with CD (P <0.001), but not in those 
with UC (P = 0.1) (Table 5), thus confirming IL-9 
may be inflammatory or regulatory.
Using the same method, Th1, Th2 and IL-6 
cytokines were all undetectable in the 10 control 
patients, whereas a borderline level of IL-9 was 
detected in two patients.
Discussion
There is considerable debate as to whether UC and 
CD express fully polarised immunophenotypes of 
IBD, but recent studies indicate markedly increased 
levels of Th1-related cytokines and Th17 in the 
inflamed mucosa of CD patients, whereas the 
inflamed mucosa of UC patients show an increased 
production of Th2 cytokines.18
In this pilot study, IFN-γ was detected in 93% of 
the patients, only five of whom had inactive dis-
ease and were untreated. The remaining 38 were all 
being treated with mesalazine (patients treated 
with corticosteroids or immunosuppressors were 
excluded). Our findings seem to highlight a com-
mon Th1 cytokine pattern in UC and CD patients, 
thus supporting the hypothesis that the diseases 
have a common genetic background. It is known 
that protein tyrosine phosphatase non-receptor 
type 2 (PTPN2) gene variants are associated with 
susceptibility to both,19 and PTPN2 regulates IFN-
γ-induced signalling and barrier function in intesti-
nal epithelial cells. The loss of PTPN2 promotes 
IFN-γ-induced STAT signalling and the secretion 
of IL-6 and macrophage chemoattractant protein 1 
(MCP-1),20 and PTPN2 protects epithelial barrier 
function in vitro by restricting the ability of IFN-γ 
to increase epithelial permeability and prevent the 
induction of the expression of the pore-forming 
protein claudin-2.21
Table 1. Demographic and clinical characteristics of study 
patients.
Ulcerative colitis Crohn’s disease
Patients (n) 23 20
M/F ratio 8/15 10/10
Mean age at diagnosis 
(years, range)
34.6 (19–58) 39.2 (14–63)
Disease activity
Inactive 4 1
Mildly active 9 9
Moderately active 7 4
Highly active 3 6
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However, current evidence strongly suggests 
that IBD is a result of a more complex mecha-
nism in genetically susceptible individuals that 
leads to alterations in the processing of enteric 
antigens, pathogenic T cell activation and chronic 
inflammation.22,23 In the absence of any input 
from the environment, resting Th0, Th1 and Th2 
are the only three attractors but, in a strongly 
polarising environment, Tregs may differentiate 
into mixed cell types associated with the Th1 or 
Th2 cell constellations. Treg cells can be main-
tained only in the presence of TCR stimulation 
delivered by APC, and IL-2 produced by other T 
cells.2,24
The levels of Th2 cytokines (IL-4, IL-5 and 
IL-13) were undetectable in the blood of our IBD 
patients. However, high levels of a plethora of 
inflammatory cytokines have been found in 
inflamed mucosa, and the complex differentiation 
of Th17 cells may be due to differences in the 
local cytokine milieu. Recent studies have shown 
that lamina propria mononuclear cells isolated 
from CD patients produce significantly less TGF-
β1 than those isolated from controls when stimu-
lated via both the CD2 and CD28 pathways, 
whereas UC patients produce more than controls 
under the same conditions.23 Other studies have 
shown that the levels of most of the transcripts for 
Th17-related cytokines are higher than normal in 
patients with UC or CD, but more abundant in 
those with UC than in those with CD; on the con-
trary, the upregulation of IFN-γ mRNA are more 
marked in the lamina propria CD4+ T cells of CD 
patients.22
On the basis of our data, IBD patients have 
detectable blood levels of IL-9 and IL-6. Circulating 
Table 2. Cytokine levels in all samples.
Name of cytokines IL-4 IL-5 IL-13 IL-9 IFN-γ IL-6
Number of the patients with negative 
value (<6 pg/mL)
43 43 43 25 (12 UC/13 CD) 3 (1 UC/2 CD) 20 (11 UC/9 CD)
Number of the patients with borderline 
value (>6 <10 pg/mL)
0 0 0 0 13 (9UC/4CD) 6 (2UC/4CD)
Number of the patients with positive 
value (>10 pg/mL)
0 0 0 18 (11 UC/7 CD) 27 (13 UC/14 CD) 17 (10 UC/7 CD)
CD, Crohn’s disease; UC, ulcerative colitis.
Table 3. Correlations between IFN-γ and disease activity.
IFN-γ Inactive (UC/CD) Mildly/moderately active (UC/CD) Highly active (UC/CD) P
Negative 1 (1/0) 2 (0/2) 0 0.045
Borderline 3 (2/1) 10 (7/3) 0  
Positive 1 (1/0) 17(9/8) 9 (3/6)  
Table 4. Correlations between IL-6 and disease activity.
IL-6 Inactive (UC/CD) Mildly/moderately active (UC/CD) Highly active (UC/CD) P
Negative 3 (2/1) 15 (7/8) 2 (2/0) 0.5
Borderline 1 (1/0) 3 (1/2) 2 (0/2)  
Positive 1 (1/0) 11 (8/3) 5 (1/4)  
Table 5. Correlations between IL-9 and disease activity by type of disease.
IL-9/CD Inactive Mildly/moderately active Highly active P
Negative 1 12 0 <0.001
Positive 0 1 6  
IL-9/UC Inactive Mildly/moderately active Highly active P
Negative 3 9 0 0.1
Positive 1 7 3  
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IL-6 was detected in 23/43 serum samples (17 pos-
itive and six borderline), but there was no correla-
tion between IL-6 positivity and disease activity 
(P = 0.5) (Table 4). Many authors have investi-
gated IL-6 levels in serum and endoscopic biopsy 
samples taken from IBD patients,25,26 and an analy-
sis of cytokine production by lamina propria mon-
onuclear cells has revealed an increase in the 
spontaneous production of IL-6, TNF-α and IL-1.27
IL-6 was detected in the serum of 13/18 IL-9-
positive patients (72.2%). Unlike those of IFN-γ 
and IL-6, the serum levels of IL-9 were always >10 
pg/mL without any borderline values, and corre-
lated with highly active disease (P <0.001).
Only 41.8% of the patients in our study were 
positive for IL-9, which suggests that a variable 
that can sporadically affect the other responses 
associated with a rigid Th1 orientation may play a 
role in IBD. IL-9 can be produced by Treg or Th17 
cells with different effects, but the IBD environ-
ment in which both active TGF-β and IL-6 are 
available promotes the development of Th17 cells.7 
However, despite the common genetic substratum 
and inflammatory role of IL-9, we found a correla-
tion between disease activity and IL-9 positivity 
only in our CD patients, which suggests that the 
same cytokine can be produced in different con-
texts. This hypothesis is supported by the findings 
of an international study showing a close associa-
tion between the IL2/IL21 locus on 4q27 and UC.28 
Interleukin-2 is the key cytokine supporting the 
survival and function of Treg cells,29 and TGF-β 
and IL-2 can also be crucial in ‘reprogramming’ 
Th2 cells to lose their characteristic profile and 
switch to IL-9 secretion or, in combination with 
IL-4, drive the differentiation of Th9 cells directly.3 
In colonic mucosa, IL-25 (IL-17E), which has been 
experimentally found to be involved in this switch, 
can downregulate Th1/Th17 immune responses in 
an IL-10-dependent manner,30 and it has also been 
found that the IL-1031 and IL-17 families22 are 
increased in the colonic mucosa of patients with 
active UC. It is therefore possible that, IL-9 can be 
produced by Th17 or modified Th2 cells in a Th1 
habitus in the presence of TCR stimulation in vivo 
and is detectable in the peripheral blood of IBD 
patients. The in vitro and in vivo hierarchy of IL-9 
production in mouse suggests that adaptive Treg 
cells consistently produce more IL-9 than Th2 
cells, but produce less than cultured T cells derived 
from TGF-β and IL-4 (Th9) or IL-6 (Th17).9
IL-9, an important regulatory cytokine in lung 
and the gastrointestinal tract that plays a role in 
inflammation and immunosuppression, is pro-
duced by Th17, Treg and modified Th2 cells.
The majority of our IBD patients were positive 
for IFN-γ, thus confirming the presence of Th1 in 
both UC and CD.
Contacts between the antigen and genetic sub-
strate are crucial for the development, progression 
and different clinical expressions of IBD.
IL-9 positivity in some IBD patients suggests 
that factors other than the TPNP2 variant may be 
involved in worsening the pro-inflammatory 
response of the bowel T cell system. Furthermore, 
our findings confirm that IL-9 may be inflamma-
tory or regulatory in human diseases.
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